Paclitaxel has been shown to inhibit proliferation and promote apoptosis of FLT3-ITD-mutated MV4–11 AML cells by suppressing the PI3K/AKT/mTOR signaling pathway [24].Bortezomib has been shown to display synergistic anti-AML cytotoxicity in vitro when combined with low-dose decitabine, Furthermore, the erlotinib complex exhibits anti-AML potential by inducing dendritic cell differentiation of leukemia cells and remodeling the immunosuppressive microenvironment [25], thereby suggesting heightened therapeutic sensitivity in the low-expression group. This evidence concerns the gene MTOR and leukemia.